AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
466.75B
Market cap466.75B
Price-Earnings ratio
74.96
Price-Earnings ratio74.96
Dividend yield
2.58%
Dividend yield2.58%
Average volume
4.19M
Average volume4.19M
High today
$266.00
High today$266.00
Low today
$262.59
Low today$262.59
Open price
$266.00
Open price$266.00
Volume
1.26M
Volume1.26M
52 Week high
$269.39
52 Week high$269.39
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

As of today, AbbVie(ABBV) shares are valued at $264.13. The company's market cap stands at 466.75B, with a P/E ratio of 74.96 and a dividend yield of 2.58%.

During the trading session on 2026-09-25, AbbVie(ABBV) shares reached a daily high of $266.00 and a low of $262.59. At a current price of $264.13, the stock is +0.6% higher than the low and still -0.7% under the high.

Trading activity shows a volume of 1.26M, compared to an average daily volume of 4.19M.

The stock's 52-week range extends from a low of $190.75 to a high of $269.39.

The stock's 52-week range extends from a low of $190.75 to a high of $269.39.

ABBV News

Reuters 5h
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO - Reuters

...

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO - Reuters
Nasdaq 22h
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?

Key Points AbbVie maintains a diversified revenue base by expanding its presence in immunology, neuroscience, and oncology to offset patent cliffs. Novo Nordi...

AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
The Motley Fool 24h
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

Choosing between AbbVie (ABBV +0.01%) and Eli Lilly and Co (LLY +2.69%) requires weighing established income against explosive growth. Both companies lead the p...

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More ABBV News

Simply Wall St 1d
AbbVie Expands AI Drug Discovery With New Partnerships And Industry Initiative

AbbVie (NYSE:ABBV) has entered a multi year collaboration with Iambic to apply AI tools to small molecule discovery in immunology, neuroscience, and oncology....

AbbVie Expands AI Drug Discovery With New Partnerships And Industry Initiative
Nasdaq 3d
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

Key Points Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that be...

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
TipRanks 3d
AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis

AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of active polyarticular juvenile idiopathic arthritis in patients two...

Nasdaq 4d
AbbVie Collaborates With Iambic On AI-Powered Discovery And Development Of Small Molecule Therapies

(RTTNews) - Monday, AbbVie Inc. (ABBV) announced a multi-year collaboration with Iambic, a clinical-stage life sciences and technology company, to accelerate th...

AbbVie Collaborates With Iambic On AI-Powered Discovery And Development Of Small Molecule Therapies
Nasdaq 6d
AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

Key Points AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful imp...

AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.